Xeris Pharmaceuticals XERS 深 沪
已收盘 04-02 16:00:00 美东时间
6.04
0.000
0.00%
华盛通- 最 高6.14
- 今 开5.90
- 成交量 133.88万股
- 最 低 5.88
- 昨 收 6.04
- 总市值 10.41亿
- 52周最高 10.08
- 市盈率 静 1887.50
- 换手率 0.78%
- 52周最低 3.95
- 委 比 -21.10%
- 总股本 1.72亿
- 历史最高 27.983
- 量 比 0.64
- 振 幅 4.30%
- 历史最低 0.9701
- 每 手 1
- 风险率 1.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xeris Pharmaceuticals Earnings Call Highlights Rapid Growth
Xeris Pharmaceuticals (($XERS)) has held its Q4 earnings call. Read on for the ...
03-09 08:21
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Xeris Biopharma Holdings Q4 Earnings Assessment
The earnings results for Xeris Biopharma Holdings (NASDAQ:XERS) for Q4 were mad...
03-02 20:02
Xeris Biopharma Holdings Sees FY2026 Sales $375.000M-$390.000M vs $368.100M Est
Xeris Biopharma Holdings (NASDAQ:XERS) sees FY2026 sales of $375.000 million-$390.000 million vs $368.100 million analyst estimate.
03-02 20:01
Xeris Biopharma Holdings Q4 EPS $0.06 Beats $0.04 Estimate, Sales $85.807M Beat $82.340M Estimate
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 62.16 percent. This is a 300 percent increase over losses of $(0.03) per share
03-02 20:01
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
Why Are Shares Of Xeris Biopharma Falling Friday?
Xeris Biopharma Holdings shares are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.
02-28 01:29
Xeris Biopharma's Subsidiaries, Xeris Pharmaceuticals And Strongbridge Dublin Limited, File Recorlev Patent Infringement Lawsuit; Filed Patent Infringement Lawsuit Related To Recorlev Against Torrent Pharmaceuticals & Somerset Therapeutics
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced
02-27 07:04
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Xeris Biopharma Holdings shares are trading higher after the company issued FY25 revenue guidance above estimates.
Xeris Biopharma Holdings shares are trading higher after the company issued FY2...
01-09 02:17
